Filing Details

Accession Number:
0001104659-22-092614
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-18 17:15:38
Reporting Period:
2022-08-16
Accepted Time:
2022-08-18 17:15:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1356576 Supernus Pharmaceuticals Inc. SUPN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1539937 A. Jack Khattar C/O Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
Rockville MD 20850
President, Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-16 39,530 $0.00 799,431 No 4 M Direct
Common Stock Disposition 2022-08-16 9,182 $34.01 790,249 No 4 M Direct
Common Stock Disposition 2022-08-16 14,690 $34.01 775,559 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Appreciation Right Disposition 2022-08-16 39,530 $0.00 39,530 $7.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,895 2023-02-05 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,047,700 Indirect By the KBT Trust
Common Stock 4,000 Indirect By son
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
  2. Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
  5. The stock appreciation right vested in four equal annual installments beginning on February 5, 2014.